{"id":16666,"date":"2023-06-01T08:18:57","date_gmt":"2023-06-01T12:18:57","guid":{"rendered":"https:\/\/ifintechworld.com\/markets\/is-merck-stock-a-better-pick-over-abbv\/"},"modified":"2023-06-01T08:18:58","modified_gmt":"2023-06-01T12:18:58","slug":"is-merck-stock-a-better-pick-over-abbv","status":"publish","type":"post","link":"https:\/\/ifintechworld.com\/?p=16666","title":{"rendered":"Is Merck Stock A Better Pick Over ABBV?"},"content":{"rendered":"<div>\n<p>We believe that <strong data-ga-track=\"ExternalLink:https:\/\/www.trefis.com\/data\/companies\/ABBV\/\">AbbVie stock <\/strong>(NYSE: ABBV) is a better pick than its industry peer, <strong data-ga-track=\"ExternalLink:https:\/\/www.trefis.com\/data\/companies\/MRK\/\">Merck stock<\/strong><strong> <\/strong>(NYSE: MRK). MRK stock trades at a slightly higher valuation of <strong>4.8x<\/strong> trailing revenues, compared to <strong>4.2x<\/strong> for AbbVie<fbs-ticker data-name=\"ABBV\" data-href=\"https:\/\/www.forbes.com\/companies\/abbvie\" data-type=\"stock\"><br \/>\n  ABBV<br \/>\n <\/fbs-ticker>, and this valuation gap will likely narrow over time in favor of AbbVie, in our view. Looking at stock returns, Merck stock has fared better than AbbVie, and both have underperformed the broader indices. While MRK is down 2% this year, ABBV is down 16%, and the S&amp;P500 index is up 10%. There is more to the comparison, and in the sections below, we discuss why we believe ABBV stock will offer higher returns than MRK stock in the next three years. We compare a slew of factors, such as historical revenue growth, returns, and valuation, in an interactive dashboard analysis of <strong data-ga-track=\"ExternalLink:https:\/\/www.trefis.com\/data\/companies\/MRK\/no-login-required\/8Jjixxyy\/Merck-vs-AbbVie-With-Return-Forecast-Of-31-AbbVie-Is-A-Better-Bet?fromforbesandarticle=trefis230601\">Merck vs. AbbVie<\/strong>: <strong>Which Stock Is A Better Bet?<\/strong> Parts of the analysis are summarized below.<\/p>\n<p><strong>1. AbbVie\u2019s Revenue Growth Is Better<\/strong><\/p>\n<ul>\n<li>AbbVie\u2019s revenue growth has been better, with a <strong>21.2%<\/strong> average annual growth rate in the last three years, compared to <strong>15.1%<\/strong> for Merck.<\/li>\n<li>AbbVie\u2019s revenue growth has been buoyed by its Allergan<fbs-ticker data-name=\"AGN\" data-href=\"https:\/\/www.forbes.com\/companies\/allergan\" data-type=\"stock\"><br \/>\n   AGN<br \/>\n  <\/fbs-ticker> acquisition in 2020.<\/li>\n<li>The company is best known for its blockbuster drug \u2013 Humira \u2013 used to treat rheumatoid arthritis and Crohn\u2019s disease, among others. Humira garnered $21.2 billion in 2022 sales, reflecting a 3% y-o-y growth. Now, Humira\u2019s biosimilar has already hit the European and U.S. markets, weighing on the company\u2019s sales.<\/li>\n<li>Merck, over the recent years, has benefited from the label expansion of Keytruda and strong demand for vaccines, primarily Gardasil.<\/li>\n<li>However, if we look at the last twelve-month period, Merck fares better with sales growth of <strong>7.2%<\/strong> vs. no growth for AbbVie.<\/li>\n<li>Keytruda alone garnered $21 billion in sales in 2022, growing at a solid 22% y-o-y. Gardasil accounted for $7 billion in sales last year.<\/li>\n<li>Merck saw a $6 billion contribution from sales of Lagevrio \u2013 its Covid-19 antiviral pill.<\/li>\n<li>Our <strong data-ga-track=\"ExternalLink:https:\/\/www.trefis.com\/data\/companies\/ABBV\/no-login-required\/2xAUeULm\/AbbVie-ABBV-Revenue-Comparison?fromforbesandarticle=trefis230601\">AbbVie Revenue Comparison<\/strong> and <strong data-ga-track=\"ExternalLink:https:\/\/www.trefis.com\/data\/companies\/MRK\/no-login-required\/v9CoffFI\/Merck-MRK-Revenue-Comparison?fromforbesandarticle=trefis230601\">Merck Revenue Comparison<\/strong> dashboards provide more insight into the companies\u2019 sales.<\/li>\n<li>Looking forward, Merck will see Lagevrio\u2019s sales decline in 2023 and beyond. Some other drugs, including Januvia\/Janumet, are also likely to see a slowdown in sales, with increased competition. However, Keytruda is expected to see continued market share gains in the near term, aiding the company\u2019s top-line growth.<\/li>\n<li>For AbbVie, more Humira biosimilars are expected to enter the U.S. this year, likely resulting in a significant drop in the drug\u2019s sales over the coming years.<\/li>\n<li>That said, AbbVie is prepared to combat this biosimilar impact with its Allergan acquisition in 2020, giving it access to Botox, a multi-billion dollar product. Furthermore, its relatively new drugs \u2013 Skyrizi and Rinvoq \u2013 used to treat plaque psoriasis and rheumatoid arthritis, are gaining market share. For perspective, these three products garnered $13.0 billion in 2022, reflecting about 40% y-o-y growth.<\/li>\n<li>Overall, 2023 will be a painful year for AbbVie, with a decline in sales due to Humira biosimilars, but it will likely return to growth from 2024 with its relatively new drugs gaining market share.<\/li>\n<\/ul>\n<p><strong>2. AbbVie Is More Profitable <\/strong><\/p>\n<ul>\n<li>AbbVie\u2019s operating margin declined from <strong>39%<\/strong> in 2019 to <strong>31.2%<\/strong> in 2022, while Merck\u2019s operating margin rose from <strong>18.7%<\/strong> to <strong>30.3%<\/strong> over this period.<\/li>\n<li>Looking at the last twelve-month period, AbbVie\u2019s operating margin of <strong>28.5%<\/strong> fares marginally better than <strong>27.7%<\/strong> for Merck.<\/li>\n<li>AbbVie\u2019s 2019 operating margin of 39% was higher due to an $890 million other income recorded in the financials.<\/li>\n<li>Our <strong data-ga-track=\"ExternalLink:https:\/\/www.trefis.com\/data\/companies\/ABBV\/no-login-required\/VwAP6QRJ\/AbbVie-ABBV-Operating-Income-Comparison?fromforbesandarticle=trefis230601\">AbbVie Operating Income Comparison<\/strong><strong> <\/strong>and <strong data-ga-track=\"ExternalLink:https:\/\/www.trefis.com\/data\/companies\/MRK\/no-login-required\/tf2HHRXR\/Merck-MRK-Operating-Income-Comparison?fromforbesandarticle=trefis230601\">Merck Operating Income Comparison<\/strong> dashboards have more details.<\/li>\n<li>AbbVie\u2019s free cash flow margin of <strong>42.7%<\/strong> is higher than <strong>27.1%<\/strong> for Merck.<\/li>\n<li>Looking at financial risk, Merck fares better with its <strong>11.1%<\/strong> debt as a percentage of equity lower than <strong>25.8%<\/strong> for AbbVie, and its <strong>10.8%<\/strong> cash as a percentage of assets higher than <strong>5.0% <\/strong>for the latter, implying that Merck has a better debt position and more cash cushion.<\/li>\n<\/ul>\n<p><strong>3. The Net of It All<\/strong><\/p>\n<ul>\n<li>We see that AbbVie has demonstrated better revenue growth, is more profitable, and is trading at a comparatively lower valuation multiple. On the other hand, Merck has a better debt position and cash cushion.<\/li>\n<li>Now, looking at prospects, using P\/S as a base, due to high fluctuations in P\/E and P\/EBIT, we believe AbbVie is the better choice of the two, primarily because of its slightly lower valuation and promising new drugs. Also, it appears that the investors have already priced in Humira\u2019s biosimilar risks.<\/li>\n<li>If we compare the current valuation multiples to the historical averages, AbbVie fares better, with its stock currently trading at <strong>4.2x<\/strong> trailing revenues vs. the last five-year average of <strong>5.3x. <\/strong>In contrast, Merck stock trades at <strong>4.8x<\/strong> trailing revenues vs. the last five-year average of <strong>5.2x<\/strong>.<\/li>\n<li>Our <strong data-ga-track=\"ExternalLink:https:\/\/www.trefis.com\/data\/companies\/ABBV\/no-login-required\/dbIQkEew\/AbbVie-ABBV-Valuation-Ratios-Comparison?fromforbesandarticle=trefis230601\">AbbVie Valuation Ratios Comparison<\/strong> and <strong data-ga-track=\"ExternalLink:https:\/\/www.trefis.com\/data\/companies\/MRK\/no-login-required\/MAghWbdS\/Merck-MRK-Valuation-Ratios-Comparison?fromforbesandarticle=trefis230601\">Merck Valuation Ratios Comparison<\/strong> have more details.<\/li>\n<\/ul>\n<p><fbs-ad position=\"inread\" progressive=\"\" ad-id=\"article-0-inread\" aria-hidden=\"true\" role=\"presentation\"><\/fbs-ad><\/p>\n<p>While ABBV may outperform MRK in the next three years, it is helpful to see how <strong data-ga-track=\"ExternalLink:https:\/\/www.trefis.com\/data\/companies\/ABBV\/topic\/peer-comparisons\">AbbVie\u2019s Peers<\/strong> fare on metrics that matter. You will find other valuable comparisons for companies across industries at <strong data-ga-track=\"ExternalLink:https:\/\/www.trefis.com\/data\/topic\/peer-comparisons\">Peer Comparisons<\/strong><strong>.<\/strong><\/p>\n<p>Given the higher inflation and the Fed raising interest rates, MRK has seen a 2% fall this year. But can it drop from here? See how low Merck stock can go by comparing its decline in previous market crashes. Here is a performance summary of all stocks in previous market crashes.<\/p>\n<p>What if you\u2019re looking for a high-performance portfolio with a low downside instead? Here\u2019s a <strong data-ga-track=\"ExternalLink:https:\/\/www.trefis.com\/data\/companies\/PORTFOLIOS\/no-login-required\/BPo8U0Xc\/Reinforced-Value-Portfolio-with-439-Return-Since-2016-vs-87-for-S-P-500?fromforbesandarticle=trefis230601\">reinforced value portfolio<\/strong> that has beaten the market consistently while limiting losses during periods of sharp market declines.<\/p>\n<p>Invest with <strong>Trefis <\/strong><strong data-ga-track=\"ExternalLink:https:\/\/dashboards.trefis.com\/data\/companies\/PORTFOLIOS\/no-login-required\/M7MacZNG?fromforbes\">Market Beating Portfolios<\/strong><\/p>\n<p>See all <strong>Trefis <\/strong><strong data-ga-track=\"ExternalLink:https:\/\/dashboards.trefis.com\/data\/price-estimates?fromforbes\">Price Estimates<\/strong><\/p>\n<\/div>\n<p>Read the full article <a href=\"https:\/\/www.forbes.com\/sites\/greatspeculations\/2023\/06\/01\/is-merck-stock-a-better-pick-over-abbv\/\" target=\"_blank\" rel=\"noopener\">here<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>We believe that AbbVie stock (NYSE: ABBV) is a better pick than its industry peer, Merck stock (NYSE: MRK). MRK stock trades at a slightly higher valuation of 4.8x trailing revenues, compared to 4.2x for AbbVie ABBV , and this valuation gap will likely narrow over time in favor of AbbVie, in our view. Looking [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":16667,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[241],"tags":[83],"class_list":["post-16666","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-markets","tag-featured"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v20.6 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Is Merck Stock A Better Pick Over ABBV? | iFintechWorld<\/title>\n<meta name=\"description\" content=\"We believe that AbbVie stock (NYSE: ABBV) is a better pick than its industry peer, Merck stock (NYSE: MRK). MRK stock trades at a slightly higher\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ifintechworld.com\/?p=16666\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Is Merck Stock A Better Pick Over ABBV? | iFintechWorld\" \/>\n<meta property=\"og:description\" content=\"We believe that AbbVie stock (NYSE: ABBV) is a better pick than its industry peer, Merck stock (NYSE: MRK). MRK stock trades at a slightly higher\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ifintechworld.com\/?p=16666\" \/>\n<meta property=\"og:site_name\" content=\"iFintechWorld\" \/>\n<meta property=\"article:published_time\" content=\"2023-06-01T12:18:57+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-06-01T12:18:58+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/06\/1685621938_0x0.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"798\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"News Room\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"News Room\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/ifintechworld.com\/?p=16666#article\",\"isPartOf\":{\"@id\":\"https:\/\/ifintechworld.com\/?p=16666\"},\"author\":{\"name\":\"News Room\",\"@id\":\"https:\/\/ifintechworld.com\/#\/schema\/person\/6224724fd4116361255b179dc5c70b61\"},\"headline\":\"Is Merck Stock A Better Pick Over ABBV?\",\"datePublished\":\"2023-06-01T12:18:57+00:00\",\"dateModified\":\"2023-06-01T12:18:58+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/ifintechworld.com\/?p=16666\"},\"wordCount\":929,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/ifintechworld.com\/#organization\"},\"keywords\":[\"Featured\"],\"articleSection\":[\"Markets\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/ifintechworld.com\/?p=16666#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/ifintechworld.com\/?p=16666\",\"url\":\"https:\/\/ifintechworld.com\/?p=16666\",\"name\":\"Is Merck Stock A Better Pick Over ABBV? | iFintechWorld\",\"isPartOf\":{\"@id\":\"https:\/\/ifintechworld.com\/#website\"},\"datePublished\":\"2023-06-01T12:18:57+00:00\",\"dateModified\":\"2023-06-01T12:18:58+00:00\",\"description\":\"We believe that AbbVie stock (NYSE: ABBV) is a better pick than its industry peer, Merck stock (NYSE: MRK). MRK stock trades at a slightly higher\",\"breadcrumb\":{\"@id\":\"https:\/\/ifintechworld.com\/?p=16666#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ifintechworld.com\/?p=16666\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ifintechworld.com\/?p=16666#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/ifintechworld.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Is Merck Stock A Better Pick Over ABBV?\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/ifintechworld.com\/#website\",\"url\":\"https:\/\/ifintechworld.com\/\",\"name\":\"Repay Down\",\"description\":\"Latest Personal Finance News, Tips and Updates\",\"publisher\":{\"@id\":\"https:\/\/ifintechworld.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/ifintechworld.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/ifintechworld.com\/#organization\",\"name\":\"Repay Down\",\"url\":\"https:\/\/ifintechworld.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/ifintechworld.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/rep-logo-dark.png\",\"contentUrl\":\"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/rep-logo-dark.png\",\"width\":558,\"height\":90,\"caption\":\"Repay Down\"},\"image\":{\"@id\":\"https:\/\/ifintechworld.com\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/ifintechworld.com\/#\/schema\/person\/6224724fd4116361255b179dc5c70b61\",\"name\":\"News Room\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/ifintechworld.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/avatar_user_1_1682606986-96x96.png\",\"contentUrl\":\"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/avatar_user_1_1682606986-96x96.png\",\"caption\":\"News Room\"},\"sameAs\":[\"https:\/\/ifintechworld.com\"],\"url\":\"https:\/\/ifintechworld.com\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Is Merck Stock A Better Pick Over ABBV? | iFintechWorld","description":"We believe that AbbVie stock (NYSE: ABBV) is a better pick than its industry peer, Merck stock (NYSE: MRK). MRK stock trades at a slightly higher","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ifintechworld.com\/?p=16666","og_locale":"en_US","og_type":"article","og_title":"Is Merck Stock A Better Pick Over ABBV? | iFintechWorld","og_description":"We believe that AbbVie stock (NYSE: ABBV) is a better pick than its industry peer, Merck stock (NYSE: MRK). MRK stock trades at a slightly higher","og_url":"https:\/\/ifintechworld.com\/?p=16666","og_site_name":"iFintechWorld","article_published_time":"2023-06-01T12:18:57+00:00","article_modified_time":"2023-06-01T12:18:58+00:00","og_image":[{"width":1200,"height":798,"url":"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/06\/1685621938_0x0.jpg","type":"image\/jpeg"}],"author":"News Room","twitter_card":"summary_large_image","twitter_misc":{"Written by":"News Room","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ifintechworld.com\/?p=16666#article","isPartOf":{"@id":"https:\/\/ifintechworld.com\/?p=16666"},"author":{"name":"News Room","@id":"https:\/\/ifintechworld.com\/#\/schema\/person\/6224724fd4116361255b179dc5c70b61"},"headline":"Is Merck Stock A Better Pick Over ABBV?","datePublished":"2023-06-01T12:18:57+00:00","dateModified":"2023-06-01T12:18:58+00:00","mainEntityOfPage":{"@id":"https:\/\/ifintechworld.com\/?p=16666"},"wordCount":929,"commentCount":0,"publisher":{"@id":"https:\/\/ifintechworld.com\/#organization"},"keywords":["Featured"],"articleSection":["Markets"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/ifintechworld.com\/?p=16666#respond"]}]},{"@type":"WebPage","@id":"https:\/\/ifintechworld.com\/?p=16666","url":"https:\/\/ifintechworld.com\/?p=16666","name":"Is Merck Stock A Better Pick Over ABBV? | iFintechWorld","isPartOf":{"@id":"https:\/\/ifintechworld.com\/#website"},"datePublished":"2023-06-01T12:18:57+00:00","dateModified":"2023-06-01T12:18:58+00:00","description":"We believe that AbbVie stock (NYSE: ABBV) is a better pick than its industry peer, Merck stock (NYSE: MRK). MRK stock trades at a slightly higher","breadcrumb":{"@id":"https:\/\/ifintechworld.com\/?p=16666#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ifintechworld.com\/?p=16666"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/ifintechworld.com\/?p=16666#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ifintechworld.com\/"},{"@type":"ListItem","position":2,"name":"Is Merck Stock A Better Pick Over ABBV?"}]},{"@type":"WebSite","@id":"https:\/\/ifintechworld.com\/#website","url":"https:\/\/ifintechworld.com\/","name":"Repay Down","description":"Latest Personal Finance News, Tips and Updates","publisher":{"@id":"https:\/\/ifintechworld.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ifintechworld.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/ifintechworld.com\/#organization","name":"Repay Down","url":"https:\/\/ifintechworld.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/ifintechworld.com\/#\/schema\/logo\/image\/","url":"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/rep-logo-dark.png","contentUrl":"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/rep-logo-dark.png","width":558,"height":90,"caption":"Repay Down"},"image":{"@id":"https:\/\/ifintechworld.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/ifintechworld.com\/#\/schema\/person\/6224724fd4116361255b179dc5c70b61","name":"News Room","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/ifintechworld.com\/#\/schema\/person\/image\/","url":"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/avatar_user_1_1682606986-96x96.png","contentUrl":"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/avatar_user_1_1682606986-96x96.png","caption":"News Room"},"sameAs":["https:\/\/ifintechworld.com"],"url":"https:\/\/ifintechworld.com\/?author=1"}]}},"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/ifintechworld.com\/index.php?rest_route=\/wp\/v2\/posts\/16666","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ifintechworld.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ifintechworld.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ifintechworld.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/ifintechworld.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=16666"}],"version-history":[{"count":1,"href":"https:\/\/ifintechworld.com\/index.php?rest_route=\/wp\/v2\/posts\/16666\/revisions"}],"predecessor-version":[{"id":16668,"href":"https:\/\/ifintechworld.com\/index.php?rest_route=\/wp\/v2\/posts\/16666\/revisions\/16668"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ifintechworld.com\/index.php?rest_route=\/wp\/v2\/media\/16667"}],"wp:attachment":[{"href":"https:\/\/ifintechworld.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=16666"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ifintechworld.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=16666"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ifintechworld.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=16666"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}